Trials / Active Not Recruiting
Active Not RecruitingNCT03769103
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- British Columbia Cancer Agency · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Osimertinib | Daily oral osimertinib |
| RADIATION | Stereotactic radiotherapy | 1-5 fractions of stereotactic radiotherapy |
Timeline
- Start date
- 2019-03-19
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2018-12-07
- Last updated
- 2024-10-31
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03769103. Inclusion in this directory is not an endorsement.